March 2026
The U.S. automated cell counting market size was estimated at USD 1.42 billion in 2025 and is predicted to increase from USD 1.62 billion in 2026 to approximately USD 5.38 billion by 2035, expanding at a CAGR of 14.24% from 2026 to 2035.

The market is growing due to increasing biotechnology research, expanding pharmaceutical development, and strong laboratory infrastructure. Rising demand for precise and rapid cell analysis in research and clinical laboratories is encouraging the adoption of automated cell counting technologies.
The market refers to the industry focused on instruments and technologies used to automatically measure and analyze cell numbers and viability in laboratories across the United States for research, diagnostics, and biopharmaceutical applications. The U.S. automated cell counting market is growing due to increasing investments in biotechnology, pharmaceutical development, and cell-based research. Laboratories require accurate and rapid cell analysis to support drug discovery, biologics production, and clinical studies. Automated cell counting systems help improve efficiency, reduce manual workload, and ensure consistent results. In addition, the presence of advanced research infrastructure and rising demand for reliable laboratory technologies further support market growth.
Artificial intelligence can enhance the market by improving the precision and efficiency of cell analysis. Advanced data processing tools help laboratories quickly interpret large volumes of cell imaging data, enabling faster research outcomes. These technologies can also streamline laboratory workflows, support consistent results, and assist researchers in identifying complex cell patterns, which strengthens their role in biotechnology, pharmaceutical research, and clinical laboratories across the United States.
| Table | Scope |
| Market Size in 2026 | USD 1.62 Billion |
| Projected Market Size in 2035 | USD 5.38 Billion |
| CAGR (2026 - 2035) | 14.24% |
| Historical Data | 2020 - 2023 |
| Base Year | 2025 |
| Forecast Period | 2026 - 2035 |
| Measurable Values | USD Millions/Units/Volume |
| Market Segmentation | By-Product, By Application, By End Use |
| Top Key Players | Thermo Fisher Scientific, DeNovix, Abbott Laboratories, Bio-Rad Laboratories, HORIBA, Danaher Corporation, F. Hoffmann-La Roche Ltd |
Why Did the Consumables & Accessories Segment Dominate in the U.S. Automated Cell Counting Market in 2025?
The consumables & accessories segment dominated the market in 2025 due to their frequent and repeated use in laboratory workflows. Items such as counting slides, reagents, and sample preparation materials must be regularly replaced, creating consistent demand. Growing research activities in biotechnology and pharmaceutical laboratories also increase the consumption of these products, supporting the segment’s leading market share.
Instruments
The instruments segment is expected to grow at the fastest CAGR in the market due to increasing adoption of advanced laboratory equipment in biotechnology and pharmaceutical research. Research institutions are investing in modern automated systems to improve efficiency, accuracy, and workflow productivity. In addition, continuous technological improvements and the growing need for high-performance cell analysis tools are encouraging laboratories to upgrade to advanced automated cell counting instruments.
What Made the Cell Line Development Segment Dominant in the U.S. Automated Cell Counting Market in 2025?
The cell line development segment dominated the market in 2025 due to the increasing use of cultured cells in biologics production, vaccine research, and therapeutics development. Accurate monitoring of cell growth, viability, and concentration is essential during cell line optimization. Automated cell counting systems help researchers obtain reliable and consistent data, making them widely used in biotechnology and pharmaceutical laboratories involved in cell-based product development.
In January 2024, Abzena introduced a new cell line development platform named AbZelectPRO. The platform is designed to accelerate the creation of cell lines used in producing recombinant proteins and antibodies, helping improve efficiency in biopharmaceutical manufacturing.
Stem Cell Research
The stem cell research segment is expected to grow at the fastest CAGR in the market due to an increasing focus on regenerative medicine and advanced therapeutic development. Stem cell studies require precise monitoring of cell concentration and viability during experiments. Automated cell counting systems provide accurate and consistent measurements, which help researchers maintain quality and efficiency in stem cell culture, expansion, and clinical research applications.
How Does the Pharmaceutical & Biotechnology Companies Segment Dominate the U.S. Automated Cell Counting Market in 2025?
The pharmaceutical & biotechnology companies segment dominated the market in 2025 due to the extensive use of cell analysis in drug discovery, biologics production, and vaccine development. These companies require precise monitoring of cell growth and viability during the research and manufacturing process. Automated cell counting systems help improve accuracy, efficiency, and consistency in laboratory workflows, making them essential tools in pharmaceutical and biotechnology research facilities.
Hospitals & Diagnostic Laboratories
The hospitals & diagnostic laboratories segment is expected to grow at the fastest CAGR due to increased demand for accurate and rapid laboratory testing. Growing patient volumes and the need for efficient diagnostic procedures encourage healthcare facilities to adopt automated technologies. Automated cell counting systems help improve testing efficiency, reduce manual errors, and support reliable cell analysis in clinical diagnostic and routine laboratory workflows.
The U.S. automated cell counting market is experiencing rapid growth, driven by increasing adoption in biopharma, oncology research, and clinical diagnostics, which demand higher accuracy, speed, and standardization.
California Market Trends
California's market thrives due to a high concentration of biotech firms and research institutions in the Bay Area. Robust funding for cell-based research, particularly in stem cells and oncology, drives the adoption of automated imaging systems for faster, more accurate cell viability, enhancing laboratory efficiency, and reducing reliance on manual counting.
Massachusetts
The Massachusetts market is growing rapidly, supported by the Boston area's extensive biotech, pharma, and academic research presence. Increased investment in cell therapy, gene therapy, and bioprocessing requires precise, high-throughput automated cell counters for quality control, propelling demand for sophisticated imaging, AI-based analytics, and associated consumables

| Companies | Headquarters | Offerings |
| Thermo Fisher Scientific | Massachusetts, USA | Provides automated cell counters, laboratory instruments, reagents, and cell analysis technologies widely used in biotechnology, pharmaceutical research, and clinical laboratories. |
| DeNovix | Delaware, USA | Develops compact laboratory instruments, including automated cell counting systems, spectrophotometers, and fluorescence-based analysis tools for life science research. |
| Abbott Laboratories | Illinois, USA | Offers diagnostic equipment, laboratory analyzers, and healthcare testing systems used in hospitals, clinical laboratories, and research facilities. |
| Bio-Rad Laboratories | California, USA | Produces automated cell counting instruments, reagents, and laboratory research tools supporting cell biology, molecular biology, and diagnostic applications. |
| ChemoMetec | Allerød, Denmark | Specializes in automated cell counting and analysis instruments designed for biopharmaceutical manufacturing, cell therapy, and research laboratories. |
| HORIBA | Kyoto, Japan | Manufactures analytical and measurement instruments, including hematology analyzers and laboratory diagnostic equipment used for cell analysis and testing. |
| Danaher Corporation | D.C., USA | Through subsidiaries such as Beckman Coulter, it provides advanced cell analysis systems, flow cytometry platforms, and laboratory automation technologies. |
| F. Hoffmann-La Roche Ltd. | Basel, Switzerland | Offers diagnostic instruments, laboratory testing platforms, and research technologies supporting biomedical research and clinical diagnostics. |
By-Product
By Application
By End Use
March 2026
March 2026
February 2026
February 2026